Possible Long Targets Set For SBBP

Strongbridge Biopharma Plc operates as a commercial-stage biopharmaceutical company, which focuses on the development and commercialization of therapies for rare diseases. Its pipeline is comprised of Keveyis, Macrilen, Recorlev, and Veldoreotide. The company was founded on May 26, 2015 and is headquartered in Lower Southampton, PA.

SHORT INTEREST
1.13M 08/15/19

Average Recommendation: BUY

Average Target Price: 13.71

P/E Current
7.53

P/E Ratio (with extraordinary items)
6.21

P/E Ratio (without extraordinary items)
6.51